ACRS
What one share of Aclaris Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company focused on discovering and developing novel small and large molecule product candidates for immuno-inflammatory diseases. Our proprietary KINect drug discovery platform coupled with our integrated discovery approach to small and large molecules enables us to identify and advance product candidates designed to have superior target affinity, specificity and potency.
Aclaris Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.06 |
|---|---|
| Profit | −$0.59 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.48 |
| Cash and investments | $0.14 |
| Book value | $0.89 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$2.25 | $0.01 | −$1.63 | — | $6.50 |
| 2017 | $0.06 | −$2.44 | $0.04 | −$1.99 | — | $7.30 |
| 2018 | $0.19 | −$4.03 | $0.04 | −$3.10 | — | $5.22 |
| 2019 | $0.10 | −$3.90 | $0.04 | −$2.37 | — | $1.69 |
| 2020 | $0.15 | −$1.20 | $0.01 | −$0.92 | — | $0.83 |
| 2021 | $0.12 | −$1.60 | $0.01 | −$0.92 | — | $3.22 |
| 2022 | $0.46 | −$1.33 | $0.01 | −$1.05 | — | $2.96 |
| 2023 | $0.45 | −$1.27 | $0.02 | −$1.14 | — | $2.22 |
| 2024 | $0.24 | −$1.71 | $0.00 | −$0.26 | — | $1.44 |
| 2025 | $0.06 | −$0.53 | $0.00 | −$0.39 | — | $0.86 |